Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TestICUs: Early Testosterone Gel in Critically Ill Patients
2024-519156-93-00Phase 2Authorised
- Sponsor
- Centre Hospitalier Universitaire de Clermont-Ferrand
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute quadriplegic myopathy (CIM), Critical Illness Polyneuropathy (CIP), muscle weakness and 1 more comparing Testosterone gel with Placebo gel / standard care (2 arms). Primary endpoint: Primary: 6-minute walk distance at 3 months. Planned start Dec 2024; status: authorised.
02
Drugs
AndroForte
03
Conditions
acute quadriplegic myopathy (CIM)Critical Illness Polyneuropathy (CIP)muscle weaknessventilator dependence (PMV)
Beyond the preview
Go deeper on 2024-519156-93-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519156-93-00.